Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress Inhibrx Biosciences is preparing to present groundbreaking findings on a novel drug combination for Ewing Sarcoma at the ESMO conference in March 2026.

Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress #USA #San_Diego #Inhibrx #ESMO_Congress #Ewing_Sarcoma

Inhibrx Biosciences Reveals Key Updates on Oncology Drug Programs Inhibrx Biosciences provides significant progress updates on their clinical programs for INBRX-106 and ozekibart, aiming to enhance cancer treatment.

Inhibrx Biosciences Reveals Key Updates on Oncology Drug Programs #USA #San_Diego #Inhibrx #ozekibart #INBRX-106

Inhibrx Biosciences to Present Clinical Insights at Key Conferences in November 2025 Inhibrx Biosciences will showcase its pioneering research at prestigious upcoming scientific conferences in November, highlighting innovative therapies.

Inhibrx Biosciences to Present Clinical Insights at Key Conferences in November 2025 #United_States #San_Diego #Clinical_Research #Inhibrx #DR5_Agonist

Inhibrx Biosciences Announces Financial Results for Q1 2025 with Positive Developments Ahead Inhibrx Biosciences has released its Q1 2025 financial results, showcasing a strong cash position, reduced losses, and promising clinical trial milestones ahead.

Inhibrx Biosciences Announces Financial Results for Q1 2025 with Positive Developments Ahead #USA #San_Diego #Biosciences #FinancialResults #Inhibrx

Inhibrx Biosciences Sees Leadership Changes with New Appointments Inhibrx Biosciences has announced significant changes in its leadership team, including the departure of its CSO and the appointment of new executives. Read more about the changes and their potential impact.

Inhibrx Biosciences Sees Leadership Changes with New Appointments #United_States #San_Diego #Inhibrx #Brendan_Eckelman #Carlos_Bais

Inhibrx Reports Strong Financial Results for Q4 and Fiscal Year 2024 Inhibrx Biosciences, Inc. shares updates on their financial performance for the fourth quarter and fiscal year 2024, highlighting pivotal developments.

Inhibrx Reports Strong Financial Results for Q4 and Fiscal Year 2024 #United_States #San_Diego #Inhibrx #INBX #ozekibart